AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26435241 — intervention group
Group type: COMPARATOR
Intervention: Aquacel Surgical®
Number of subjects: 111
Study 26435241 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 111
Study 24021518 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 61
Study 24021518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20970825 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic lignocaine injection
Number of subjects: 75
Study 20970825 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal saddle block
Number of subjects: 75
Study 20970825 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (Group 1)
Number of subjects: 75
Study 19086193 — intervention group
Group type: EXPERIMENTAL
Intervention: Firm foam
Number of subjects: 32
Study 19086193 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium foam
Number of subjects: 32
Study 19086193 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft foam
Number of subjects: 32
Study 19086193 — intervention group
Group type: COMPARATOR
Intervention: Solid surface
Number of subjects: 32
Study 19086193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision (eyes open vs closed)
Number of subjects: 32
Study 12382382 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ball device
Number of subjects: 42
Study 12382382 — intervention group
Group type: COMPARATOR
Intervention: Standard eye fixation induction control condition
Number of subjects: 42
Study 9593458 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet, 50 mg three times per day administered intravenously for 4 weeks
Number of subjects: 10
Study 7642328 — intervention group
Group type: EXPERIMENTAL
Intervention: Large e-PTFE membranes (Gortex) placed to cover the lesions
Number of subjects: 20
Study 7642328 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no membranes used)
Number of subjects: 20
Study 2664628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 391
Study 2664628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% levobunolol
Number of subjects: 391
Study 2664628 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 391
Study 2664628 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 391
Study 360495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of 10% glycerol in 0.9% NaCl‐‐5% glucose solutions administered twice daily for 6 days to 26 patients
Number of subjects: 51
Study 360495 — intervention group
Group type: COMPARATOR
Intervention: NaCl‐‐glucose solutions administered to 25 controls
Number of subjects: 51
Study 30916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hypertension
Number of subjects: 912
Study 30916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of hypertension
Number of subjects: 912
Study 30916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of arterial hypertension
Number of subjects: 912
Study 28361275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinal stabilization exercise program (3 days a week for 8 weeks)
Number of subjects: 38
Study 28361275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 28361275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinal stabilization exercise program
Number of subjects: 38
Study 25413168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural training programme for pain management (6 weekly group sessions supervised by a psychologist and a physiotherapist)
Number of subjects: 111
Study 25413168 — intervention group
Group type: COMPARATOR
Intervention: Ordinary GP care (control group)
Number of subjects: 111
Study 25413168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural training programme for pain management
Number of subjects: 111
Study 23331443 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 2.5 mg daily
Number of subjects: 60
Study 23331443 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 60
Study 21273355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged carotid sinus reflex (CSR) after CAS
Number of subjects: 80
Study 21273355 — intervention group
Group type: COMPARATOR
Intervention: No prolonged CSR
Number of subjects: 80
Study 21273355 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed renal impairment
Number of subjects: 80
Study 19671411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine Capsule, 0.4 g once a day for 3 months
Number of subjects: 60
Study 19671411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxymatrine)
Number of subjects: 60
Study 17094673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg alprazolam
Number of subjects: 18
Study 17094673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75 mg alprazolam
Number of subjects: 18
Study 17094673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15631714 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of Triptorelin (3.75 mg) at 6 weeks intervals in group A
Number of subjects: 46
Study 15631714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of Triptorelin (3.75 mg) at 4 weeks intervals in group B
Number of subjects: 46
Study 15631714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimes (SC and IM)
Number of subjects: 46
Study 11705848 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxyphenylretinamide (4-HPR) at 200 mg/day for 6 months (with a 3-day/month drug holiday)
Number of subjects: 0
Study 11705848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9146313 — intervention group
Group type: COMPARATOR
Intervention: Normothermic retrograde blood cardioplegia (control group)
Number of subjects: 30
Study 9146313 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minutes of global ischemia followed by reperfusion with antegrade and retrograde blood cardioplegia (preconditioned group)
Number of subjects: 30
Study 9146313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and preconditioned)
Number of subjects: 30
Study 7952601 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 7952601 — intervention group
Group type: COMPARATOR
Intervention: Beta 2-agonists
Number of subjects: 0
Study 30368332 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (YE) for 12 weeks
Number of subjects: 15
Study 29231563 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui(GV 20) and Shenting(GV 24) combined with basic treatment and regular rehabilitation
Number of subjects: 50
Study 29231563 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment and regular rehabilitation
Number of subjects: 50
Study 24158311 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating Healthy participation And Relapse Prevention at work intervention (problem-solving intervention)
Number of subjects: 158
Study 24158311 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study 22420538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) extubation protocol
Number of subjects: 75
Study 22420538 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT) including NIV if indicated
Number of subjects: 75
Study 20435231 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/d
Number of subjects: 86
Study 20435231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19863407 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (20 mg)
Number of subjects: 10
Study 19863407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16513450 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP8‐37 (333 ng.min(‐1).dL(‐1) forearm)
Number of subjects: 21
Study 16513450 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP (10 ng.min(‐1).dL(‐1) forearm) with CGRP8‐37 (300, 600, or 1200 ng.min(‐1).dL(‐1) forearm)
Number of subjects: 21
Study 16513450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16513450 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP8‐37
Number of subjects: 21
Study 14682406 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone (QVAR)
Number of subjects: 0
Study 14682406 — intervention group
Group type: COMPARATOR
Intervention: CFC-beclomethasone (Vanceril)
Number of subjects: 0
Study 10594430 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood conservation system
Number of subjects: 100
Study 10594430 — intervention group
Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 100
Study 10594430 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration (both groups)
Number of subjects: 100
Study 9496205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 200 micrograms and midazolam 0.2 mg kg‐1 (fentanyl group, n = 15)
Number of subjects: 30
Study 9496205 — intervention group
Group type: COMPARATOR
Intervention: Placebo and midazolam 0.2 mg kg‐1 (placebo group, n = 15)
Number of subjects: 30
Study 8365971 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (leucine + isoleucine + valine, 77 mg/kg)
Number of subjects: 7
Study 8365971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose, 77 mg/kg)
Number of subjects: 7
Study 2939571 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school intervention
Number of subjects: 78
Study 2939571 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only regimen
Number of subjects: 78
Study 30157844 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent medical evaluation (IME)
Number of subjects: 14
Study 30157844 — intervention group
Group type: EXPERIMENTAL
Intervention: Second opinion from an experienced GP colleague
Number of subjects: 14
Study 30157844 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of particularly challenging sick-listed patients for IME
Number of subjects: 14
Study 25818103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, smoking cessation, and exercise) with oral and written information provided in a booklet for postoperative rehabilitation.
Number of subjects: 500
Study 25818103 — intervention group
Group type: COMPARATOR
Intervention: Regular oral instructions (Control group).
Number of subjects: 500
Study 25818103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, smoking cessation, and exercise).
Number of subjects: 500
Study 23864581 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (more than 360 defined daily doses)
Number of subjects: 65754
Study 23864581 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (more than 1080 defined daily doses)
Number of subjects: 65754
Study 23864581 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in combination with other antidiabetic drugs
Number of subjects: 65754
Study 23864581 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 65754
Study 23864581 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes patients not on diabetes drugs
Number of subjects: 65754
Study 23864581 — intervention group
Group type: COMPARATOR
Intervention: Antidiabetic drugs other than metformin
Number of subjects: 65754
Study 22735495 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood stove replacement
Number of subjects: 0
Study 22735495 — intervention group
Group type: EXPERIMENTAL
Intervention: Air filters
Number of subjects: 0
Study 22735495 — intervention group
Group type: COMPARATOR
Intervention: Sham air filter placebo
Number of subjects: 0
Study 19633952 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief 2-hour discussion group for parents
Number of subjects: 46
Study 19633952 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 46
Study 18519824 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal and in vivo exposure (n = 30)
Number of subjects: 90
Study 18519824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (n = 30)
Number of subjects: 90
Study 18519824 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 30)
Number of subjects: 90
Study 16061501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital combination-fibrinolysis with facilitated PCI
Number of subjects: 164
Study 16061501 — intervention group
Group type: COMPARATOR
Intervention: Pre-hospital combination-fibrinolysis
Number of subjects: 164
Study 12769413 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0
Study 12769413 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 10365640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg/d for 1 week
Number of subjects: 29
Study 9816035 — intervention group
Group type: EXPERIMENTAL
Intervention: Amonafide at 300 mg/m2/day i.v. for 5 days, repeated at 21-day intervals for a maximum of four cycles.
Number of subjects: 0
Study 1675367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorion villus sampling
Number of subjects: 3248
Study 1675367 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 3248
Study 7003611 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg DT gamma E (intra-muscular injections for 4 days)
Number of subjects: 13
Study 7003611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injections for 4 days)
Number of subjects: 13
Study 7003611 — intervention group
Group type: EXPERIMENTAL
Intervention: DT gamma E
Number of subjects: 13
Study 31159822 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-driven NMES-robotic support to the finger joints (hand group, n=15)
Number of subjects: 30
Study 31159822 — intervention group
Group type: COMPARATOR
Intervention: EMG-driven NMES-robotic support to the wrist-elbow joints (sleeve group, n=15)
Number of subjects: 30
Study 31159822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hand and sleeve)
Number of subjects: 30
Study 31159822 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand group
Number of subjects: 30
Study 28242714 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged on-treatment SBP at 120 to 130 mm Hg (mean, 126.2 mm Hg)
Number of subjects: 17720
Study 28242714 — intervention group
Group type: COMPARATOR
Intervention: Time-averaged on-treatment SBP at 130 to 135 mm Hg (mean, 132.6 mm Hg)
Number of subjects: 17720
Study 28242714 — intervention group
Group type: COMPARATOR
Intervention: Time-averaged on-treatment SBP at 135 to 140 mm Hg (mean, 137.5 mm Hg)
Number of subjects: 17720
Study 28242714 — intervention group
Group type: COMPARATOR
Intervention: Time-averaged on-treatment SBP <120 mm Hg (mean, 116.7 mm Hg)
Number of subjects: 17720
Study 25968576 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral lipectomy (LIPO)
Number of subjects: 29
Study 25968576 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 29
Study 22904126 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity warm-up protocols performed near testing
Number of subjects: 6
Study 22904126 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a light survival coat during warm-ups
Number of subjects: 6
Study 21466926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine cues
Number of subjects: 14
Study 21466926 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective craving
Number of subjects: 14
Study 21466926 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state correlation
Number of subjects: 14
Study 18619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention comprising reviews of centers, training programmes, documents, and tailored feedback
Number of subjects: 0
Study 18619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 0
Study 17969887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gandou Decoction IV (GDIV)
Number of subjects: 61
Study 17969887 — intervention group
Group type: COMPARATOR
Intervention: Sodium dimercaptosulphonate (DMPS)
Number of subjects: 61
Study 15273208 — intervention group
Group type: EXPERIMENTAL
Intervention: Community team-based primary data collectors
Number of subjects: 23
Study 15273208 — intervention group
Group type: COMPARATOR
Intervention: Random audits
Number of subjects: 23
Study 10665617 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (sublingual)
Number of subjects: 8
Study 10665617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9309469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 15
Study 9309469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8341998 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month therapy with daily Rifater for two months, followed by isoniazid and rifampicin for four months (n = 128)
Number of subjects: 261
Study 8341998 — intervention group
Group type: COMPARATOR
Intervention: Nine-month therapy with isoniazid and rifampicin daily for nine months, supplemented by ethambutol for the first two months (n = 133)
Number of subjects: 261
Study 8341998 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial drug resistance to isoniazid
Number of subjects: 261
Study 8341998 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent multi-drug therapy
Number of subjects: 261
Study 8341998 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial resistance to isoniazid and rifampicin
Number of subjects: 261
Study 3525695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 X 10(6) IU of IFN‐alpha 2, 3 times per week for 12 weeks
Number of subjects: 76
Study 3525695 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 10(6) IU of IFN‐alpha 2, 3 times per week for 12 weeks
Number of subjects: 76
Study 3525695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 31113475 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-positive sepsis
Number of subjects: 2659
Study 31113475 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics at home
Number of subjects: 2659
Study 28625592 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstented TIPU
Number of subjects: 110
Study 28625592 — intervention group
Group type: COMPARATOR
Intervention: Stented TIPU
Number of subjects: 110
Study 28625592 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 110
Study 25839406 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir (25mg/150mg/100mg once daily) and dasabuvir (250mg twice daily) + weight-based ribavirin for 12 weeks
Number of subjects: 38
Study 25839406 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin
Number of subjects: 38
Study 24067081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline (23 ml/kg)
Number of subjects: 23
Study 24067081 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline (7 ml/kg)
Number of subjects: 23
Study 24067081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose (23 ml/kg)
Number of subjects: 23
Study 21362274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance combined with stimulating catheter (USNS group)
Number of subjects: 120
Study 21362274 — intervention group
Group type: COMPARATOR
Intervention: Stimulating catheter alone (NS group)
Number of subjects: 120
Study 19616140 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with OSA (39% of the sample)
Number of subjects: 51
Study 19616140 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 51
Study 19616140 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression severity and insomnia severity
Number of subjects: 51
Study 17182222 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly booster sessions for a further nine months
Number of subjects: 103
Study 17182222 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care with no further group meetings
Number of subjects: 103
Study 15492339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 170
Study 15492339 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 170
Study 12235221 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug combinations containing at least one new agent
Number of subjects: 0
Study 12235221 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer targeted therapies
Number of subjects: 0
Study 9555615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for one week
Number of subjects: 20
Study 9555615 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for one week
Number of subjects: 20
Study 7480963 — intervention group
Group type: EXPERIMENTAL
Intervention: r-alpha-IFN-2a (3 MU thrice weekly for 12 months)
Number of subjects: 35
Study 7480963 — intervention group
Group type: COMPARATOR
Intervention: r-alpha-IFN-2b (3 MU thrice weekly for 12 months)
Number of subjects: 35
Study 2919963 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral lipids
Number of subjects: 0
Study 2919963 — intervention group
Group type: COMPARATOR
Intervention: Control (no enteral lipids)
Number of subjects: 0
Study 31735634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg and 2.0 mg) administered monthly or on an as-needed basis (PRN)
Number of subjects: 1097
Study 31735634 — intervention group
Group type: COMPARATOR
Intervention: Dilated fundus examination (DFE) and fundus photography
Number of subjects: 1097
Study 31735634 — intervention group
Group type: COMPARATOR
Intervention: Spectral-domain OCT (SD-OCT)
Number of subjects: 1097
Study 29265836 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT) as guided self-help
Number of subjects: 242
Study 29265836 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 242
Study 28911091 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1/cisplatin
Number of subjects: 361
Study 28911091 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/cisplatin
Number of subjects: 361
Study 26258821 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin group (1 g ascorbic acid and 600 IU D‐α‐tocopherol orally 60 min before the dive)
Number of subjects: 16